ProM The ProM platform: New ways to drug the undruggable
- Coordinator
- Prosion GmbH, Germany
- Runs
- 1 April 2022 to 31 March 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190154511
What the project is doing
In the project's own words, from its summary on CORDIS.
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked. PROSION developed a disruptive platform of chemical building blocks called ProMs.
The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders. The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Prosion GmbH | Koln | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI